Patents by Inventor PHILIP Z. BROHAWN

PHILIP Z. BROHAWN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BLOOD-BASED TUMOR MUTATION BURDEN PREDICTS OVERALL SURVIVAL IN NSCLC
    Publication number: 20230145764
    Abstract: The disclosure generally relates to methods for treating non-small cell lung cancer patients based on use of blood-based tumor mutation burden to predict overall survival in patients treated with durvalumab, tremelimumab, and/or a chemotherapy agent. The disclosure also relates to methods for treating non-small cell lung cancer patients based on identification of mutations in circulating tumor DNA associated with sensitivity or resistance to immunotherapy.
    Type: Application
    Filed: October 7, 2022
    Publication date: May 11, 2023
    Inventors: Koustubh RANADE, Brandon W. HIGGS, Rajiv G. RAJA, Philip Z. BROHAWN, Han SI, Michael A. KUZIORA
  • BLOOD-BASED TUMOR MUTATION BURDEN PREDICTS OVERALL SURVIVAL IN NSCLC
    Publication number: 20200190598
    Abstract: The disclosure generally relates to methods for treating non-small cell lung cancer patients based on use of blood-based tumor mutation burden to predict overall survival in patients treated with durvalumab, tremelimumab, and/or a chemotherapy agent. The disclosure also relates to methods for treating non-small cell lung cancer patients based on identification of mutations in circulating tumor DNA associated with sensitivity or resistance to immunotherapy.
    Type: Application
    Filed: December 11, 2019
    Publication date: June 18, 2020
    Inventors: KOUSTUBH RANADE, BRANDON W. HIGGS, RAJIV G. RAJA, PHILIP Z. BROHAWN, HAN SI, MIKE KUZIORA
  • COMBINED ANTI-PLD-1 AND ANTI-CTLA-4 ANTIBODIES FOR TREATING NON-SMALL LUNG CANCER
    Publication number: 20180079814
    Abstract: A method for treating lung cancer (e.g., non-small cell lung cancer) with an anti-PD-L1 antibody (MEDI4736), alone or in combination with an anti-CTLA4 antibody (Tremelimumab), in a patient identified using a polynucleotide marker of IFNgamma.
    Type: Application
    Filed: March 31, 2016
    Publication date: March 22, 2018
    Inventors: Brandon W. Higgs, Philip Z. Brohawn, Wei Zhu, Zheng Liu, Jiaqi Huang, Katie Streicher, Yihong Yao
  • Compositions and Methods for Identifying B Cell Malignancies Responsive to B Cell Depleting Therapy
    Publication number: 20170088628
    Abstract: The invention provides compositions and methods featuring the use of miR-629 for identifying subjects responsive to B-cell depleting therapies (e.g., treatment with an anti-CD19 antibody). In other embodiments, the invention features the use of miR-629 to identify subjects as having a B cell malignancy.
    Type: Application
    Filed: December 9, 2016
    Publication date: March 30, 2017
    Inventors: Yihong Yao, Katie Streicher, Koustubh Ranade, Philip Z. Brohawn, Michael Kuziora
  • COMPOSITIONS AND METHODS FOR IDENTIFYING B CELL MALIGNANCIES RESPONSIVE TO B CELL DEPLETING THERAPY
    Publication number: 20150252431
    Abstract: The invention provides compositions and methods featuring the use of miR-629 for identifying subjects responsive to B-cell depleting therapies (e.g., treatment with an anti-CD19 antibody). In other embodiments, the invention features the use of miR-629 to identify subjects as having a B cell malignancy.
    Type: Application
    Filed: March 4, 2015
    Publication date: September 10, 2015
    Inventors: YIHONG YAO, KATIE STREICHER, KOUSTUBH RANADE, PHILIP Z. BROHAWN, MICHAEL KUZIORA